Zymeworks Inc.: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks Inc. (ZYME) presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, at ESMO Congress 2026. The study showed a 64.5% objective response rate in high-grade serous platinum-resistant ovarian cancer patients at the 6.4 mg/kg dose, with a favorable tolerability profile. The company plans to continue clinical development and is exploring strategic partnerships. A conference call is scheduled for October 27, 2026.

Original reporting
Published Oct 24, 2026, 7:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 7:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

The disclosed response rates and safety profile could accelerate partnership talks and lift the stock.

02

Market read

First report of strong Phase 1 efficacy for ZW191, likely to move ZYME stock and influence the ADC sector.

03

What to watch

Potential competition from other FRa ADCs and the need for partnership funding.

Relevance 8/10Novelty 8/10Timing: today, with investor call on Oct 27

Background

Zymeworks (Nasdaq: ZYME) is a Canadian biotech developing multifunctional therapeutics. The data were presented at ESMO 2026.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Zymeworks presented new Phase 1 data for its FRa‑targeting ADC ZW191 showing 64.5% response at 6.4 mg/kg in platinum‑resistant ovarian cancer.

Expected impact

upside pressure as investors price in strong efficacy and tolerability signals.

Evidence & confidence

First disclosure of robust Phase 1 data for a biotech with no prior public results; material for valuation and partnership prospects.

Market effects

strengthens the FRa‑targeted ADC space and may boost peer biotech valuations.

positive for Canadian biotech sector where Zymeworks is listed.

adds confidence to ADC development pipelines globally.

Counterpoint

Phase 1 data may not translate to later‑stage success; investors should watch for Phase 2 outcomes.

Key entities

  • Zymeworks Inc.

    Biotech developer of ZW191 ADC.

  • ZW191

    FRa‑targeting antibody‑drug conjugate in Phase 1.

Related articles

$ZYMEHighAI 9/10

Zymeworks Inc. (ZYME): Reports Third Quarter 2026 Financial Results

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results • 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 m

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$ZYMEMedAI 9/10

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.

$ZYMEMed

Truist raises Zymeworks stock price target on pipeline progress

Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.